Biotech Startups
9,898 companies tagged Biotech, with their investors and founders.
Qiagen manufactures enzymes and molecular biology products, plus scientific research tools and software for studying biological targets and pathways. The company serves life science researchers and laboratories.
3 investors
Stately Bio develops stem cell-derived regenerative and cell therapies using a machine learning platform that measures cell identity, behavior, and maturation directly from live-cell, label-free imaging. It partners with institutions and companies in the cell therapy field to support therapy discovery and manufacturing.
3 investors
AbbVie is a pharmaceutical company that discovers and develops medicines, working with external innovation partners to conduct research. It operates in the biopharmaceutical industry.
3 investors
Develops programmable mRNA therapies that last longer and target cells more precisely for cancer and other diseases.
3 investors
Strand is a clinical-stage biotechnology company developing programmable mRNA therapeutics for cancers and autoimmune diseases. The company has created an mRNA platform with cell-selective targeting capabilities to deliver therapeutic payloads within the body.
3 investors
Strategikon Pharma develops Clinical Maestro, a software platform for managing clinical business operations including budgeting, sourcing, contracting, and vendor management, with AI-driven cost benchmarking tools. It serves biopharmaceutical companies of all sizes and Clinical Research Organizations (CROs) involved in clinical trial outsourcing.
3 investors
Sunflower Therapeutics develops next-generation biomanufacturing technologies to reduce the complexity and cost of bringing biologic medicines to market. The platform serves entrepreneurs and established companies developing protein-based therapeutics, biomaterials, and related health and wellness products.
3 investors
Switchback Systems develops a benchtop DNA synthesis platform that combines onboard oligonucleotide synthesis and gene assembly, aimed at putting synthetic biology tools directly in scientists' hands. It targets researchers across industries such as pharmaceuticals, agriculture, and plastics, positioning itself in the synthetic biology and DNA synthesis market.
3 investors
Syantra develops the patent-pending Onco-ID platform for early cancer detection, using a biomarker and drug target discovery technology to support oncologists and pharmaceutical scientists in creating personalized, precision cancer treatments. Founded from research at the University of Calgary, it serves the oncology diagnostics and precision medicine market.
3 investors
Sydnexis is a privately held biopharmaceutical company developing SYD-101, a proprietary low-dose atropine formulation in Phase 3 clinical trials to slow the progression of pediatric progressive myopia. The company focuses on pediatric ophthalmology and children's eye care.
3 investors
Synendos is a biotech company developing selective endocannabinoid reuptake inhibitors targeting the endocannabinoid system to treat neuropsychiatric disorders. The company's lead candidate, SYT-510, is in clinical development with the goal of restoring brain function in major psychiatric and neurological conditions.
3 investors
Syneos Health is a fully integrated biopharmaceutical solutions organization that provides clinical, medical affairs, and commercial services to help pharmaceutical companies accelerate market access and patient outcomes.
3 investors
A drug discovery company founded by an experienced medicinal chemistry team with expertise in successful pharmaceutical development and clinical advancement.
3 investors
Synonym builds tools for biomanufacturing companies to model bioprocesses, run techno-economic analysis, and find production facilities. Its platform includes engineering solutions for cost and viability modeling and a facility-matching network that connects companies to fermentation and bioproduction capacity.
3 investors
Synteny develops an AI platform that models the rules of molecular recognition to design modular protein therapeutics, pairing generative biology models with high-throughput experimental validation. The company is building a pipeline of T cell receptor T cell engager (TCR TCE) therapeutics targeting intracellular proteins for solid tumour oncology and cell-specific depletion in immunology.
3 investors
Syntetica develops chemical recycling technologies to make polymers circular, starting with nylon, turning waste into new materials. The company works on green chemistry and process scale-up for industrial applications.
3 investors
Synthio Labs develops AI-powered synthesis and clinical interpretation systems for pharmaceutical interactions, offering text, voice, and video interfaces designed for healthcare professionals and patients that integrate FDA labels, drug mechanisms, and clinical literature.
3 investors
Synvivia engineers molecules designed to reprogram cells. The company operates in the biotech sector.
3 investors
T-Therapeutics develops T cell receptor-based therapeutics for cancer and autoimmune diseases using its proprietary OpTiMus platform, which identifies antigen-specific human TCRs. The company combines expertise in biopharmaceutical drug development, single cell genomics, machine learning, and structural biology.
3 investors
Tactogen develops patented new chemical entities, including benzofuran-based compositions, and conducts preclinical research and publishes data on these compounds. The company operates in the neuroscience and pharmaceutical drug development space.
3 investors
Tallac Therapeutics is a clinical-stage biopharmaceutical company developing oligonucleotide-based antibody conjugates (TRAAC candidates) designed to deliver immune-activating agents to tumor microenvironments for oncology indications. The company has two programs currently in clinical trials.
3 investors
TandemAI combines AI-driven techniques with physics-based computational methods, backed by in-house high-performance computing and wet lab operations, to support drug discovery. It offers a cloud-enabled platform for research partners and the scientific community in the pharmaceutical and biotech space.
3 investors
Tenaya Therapeutics is a clinical-stage biotechnology company developing gene therapies for inherited heart diseases, including TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy. It focuses on curative treatments addressing the genetic causes of cardiomyopathies for patients with heart disease.
3 investors
Tenpoint Therapeutics develops treatments for age-related ophthalmic conditions, with an initial focus on presbyopia care for the aging eye. The company works with eye care professionals to advance therapies in the ophthalmology market.
3 investors